{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:44:11Z","timestamp":1790394251823,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Defects in Fas function correlate with susceptibility to systemic autoimmune diseases like autoimmune lymphoproliferative syndrome (ALPS) and systemic lupus erythematosus (SLE). C57BL\/6 lpr (B6\/lpr) mice are used as an animal model of ALPS and develop a mild SLE phenotype. Involvement of interleukin-17A (IL-17A) has been suggested in both phenotypes. Since IL-17 receptor A is part of the signaling pathway of many IL-17 family members we investigated the role of IL-17 receptor signaling in disease development in mice with a B6\/lpr background. B6\/lpr mice were crossed with IL-17 receptor A deficient (IL-17RA KO) mice and followed over time for disease development. IL-17RA KO\/lpr mice presented with significantly enhanced lymphoproliferation compared with B6\/lpr mice, which was characterized by dramatic lymphadenomegaly\/splenomegaly and increased lymphocyte numbers, expansion of double-negative (DN) T-cells and enhanced plasma cell formation. However, the SLE phenotype was not enhanced, as anti-nuclear antibody (ANA) titers and induction of glomerulonephritis were not different. In contrast, levels of High Mobility Group Box 1 (HMGB1) and anti-HMGB1 autoantibodies were significantly increased in IL-17RA KO\/lpr mice compared to B6\/lpr mice. These data show that lack of IL-17RA signaling aggravates the lymphoproliferative phenotype in B6\/lpr mice but does not affect the SLE phenotype.<\/jats:p>","DOI":"10.1038\/s41598-019-39483-w","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T11:02:58Z","timestamp":1552302178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lack of IL-17 Receptor A signaling aggravates lymphoproliferation in C57BL\/6 lpr mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Odilia B. J.","family":"Corneth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Schaper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franka","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Asmawidjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M. C.","family":"Mus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8684-763X","authenticated-orcid":false,"given":"Peter","family":"Heeringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi W.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lubberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"39483_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaut.2013.06.004","volume":"45","author":"DM Gravano","year":"2013","unstructured":"Gravano, D. M. & Hoyer, K. K. Promotion and prevention of autoimmune disease by CD8+ T cells. J. Autoimmun. 45, 68\u201379 (2013).","journal-title":"J. Autoimmun."},{"key":"39483_CR2","doi-asserted-by":"crossref","unstructured":"Shah, S., Wu, E., Rao, V. K. & Tarrant, T. K. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr. Allergy Asthma Rep. 14, 462-014-0462-4 (2014).","DOI":"10.1007\/s11882-014-0462-4"},{"key":"39483_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","volume":"384","author":"L Lisnevskaia","year":"2014","unstructured":"Lisnevskaia, L., Murphy, G. & Isenberg, D. Systemic lupus erythematosus. Lancet 384, 1878\u20131888 (2014).","journal-title":"Lancet"},{"key":"39483_CR4","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.4049\/jimmunol.181.6.3811","volume":"181","author":"P Bjorck","year":"2008","unstructured":"Bjorck, P., Beilhack, A., Herman, E. I., Negrin, R. S. & Engleman, E. G. Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo. J Immunol 181, 3811\u20137 (2008).","journal-title":"J Immunol"},{"key":"39483_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1172\/JCI23025","volume":"115","author":"TK Means","year":"2005","unstructured":"Means, T. K. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115, 407\u201317 (2005).","journal-title":"J Clin Invest"},{"key":"39483_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.20021553","volume":"197","author":"L Bennett","year":"2003","unstructured":"Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711\u201323 (2003).","journal-title":"J. Exp. Med."},{"key":"39483_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/0961203308090020","volume":"17","author":"L Ronnblom","year":"2008","unstructured":"Ronnblom, L. & Pascual, V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17, 394\u20139 (2008).","journal-title":"Lupus"},{"key":"39483_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.autrev.2007.12.001","volume":"7","author":"S Yung","year":"2008","unstructured":"Yung, S. & Chan, T. M. Anti-DNA antibodies in the pathogenesis of lupus nephritis\u2013the emerging mechanisms. Autoimmun Rev 7, 317\u201321 (2008).","journal-title":"Autoimmun Rev"},{"key":"39483_CR9","doi-asserted-by":"publisher","first-page":"R71","DOI":"10.1186\/ar3332","volume":"13","author":"DA Abdulahad","year":"2011","unstructured":"Abdulahad, D. A. et al. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 13, R71 (2011).","journal-title":"Arthritis Res Ther"},{"key":"39483_CR10","doi-asserted-by":"publisher","first-page":"R184","DOI":"10.1186\/ar4015","volume":"14","author":"DA Abdulahad","year":"2012","unstructured":"Abdulahad, D. A. et al. Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations. Arthritis Res Ther 14, R184 (2012).","journal-title":"Arthritis Res Ther"},{"key":"39483_CR11","doi-asserted-by":"crossref","unstructured":"Theofilopoulos, A. N. & Dixon, F. J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37, 269-390 (1985).","DOI":"10.1016\/S0065-2776(08)60342-9"},{"key":"39483_CR12","doi-asserted-by":"crossref","unstructured":"Boggio, E. et al. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood 123, 1178-1186 (2014).","DOI":"10.1182\/blood-2013-07-518167"},{"key":"39483_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4049\/jimmunol.133.1.227","volume":"133","author":"S Izui","year":"1984","unstructured":"Izui, S. et al. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J. Immunol. 133, 227\u2013233 (1984).","journal-title":"J. Immunol."},{"key":"39483_CR14","doi-asserted-by":"crossref","unstructured":"Lubberts, E. The IL-23-IL-17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. (2015).","DOI":"10.1038\/nrrheum.2015.53"},{"key":"39483_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2014.05.004","volume":"154","author":"JC Martin","year":"2014","unstructured":"Martin, J. C., Baeten, D. L. & Josien, R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin. Immunol. 154, 1\u201312 (2014).","journal-title":"Clin. Immunol."},{"key":"39483_CR16","doi-asserted-by":"crossref","unstructured":"Hemdan, N. Y. et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun. Rev. 9, 785-792 (2010).","DOI":"10.1016\/j.autrev.2010.07.003"},{"key":"39483_CR17","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","volume":"181","author":"JC Crispin","year":"2008","unstructured":"Crispin, J. C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol 181, 8761\u20138766 (2008).","journal-title":"J. Immunol"},{"key":"39483_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123\u20131132 (2005).","journal-title":"Nat. Immunol."},{"key":"39483_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen, S. L., Jain, R., Garg, A. V. & Cua, D. J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585\u2013600 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"39483_CR20","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.4049\/jimmunol.181.9.5948","volume":"181","author":"GL Stritesky","year":"2008","unstructured":"Stritesky, G. L., Yeh, N. & Kaplan, M. H. IL-23 promotes maintenance but not commitment to the Th17 lineage. J. Immunol. 181, 5948\u20135955 (2008).","journal-title":"J. Immunol."},{"key":"39483_CR21","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1681\/ASN.2015101077","volume":"27","author":"JH Riedel","year":"2016","unstructured":"Riedel, J. H. et al. IL-17F promotes tissue injury in autoimmune kidney diseases. J. Am. Soc. Nephrol. 27, 3666\u20133677 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"39483_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1681\/ASN.2017090949","volume":"29","author":"S Krohn","year":"2018","unstructured":"Krohn, S. et al. IL-17C\/IL-17 receptor E signaling in CD4+ T cells promotes Th17 cell-driven glomerular inflammation. J. Am. Soc. Nephrol. 29, 1210\u20131222 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"39483_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10875-009-9365-x","volume":"30","author":"XQ Chen","year":"2010","unstructured":"Chen, X. Q. et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol 30, 221\u20135 (2010).","journal-title":"J Clin Immunol"},{"key":"39483_CR24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24499","volume":"60","author":"J Yang","year":"2009","unstructured":"Yang, J. et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60, 1472\u201383 (2009).","journal-title":"Arthritis Rheum"},{"key":"39483_CR25","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar2964","volume":"12","author":"K Shah","year":"2010","unstructured":"Shah, K. et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 12, R53 (2010).","journal-title":"Arthritis Res Ther"},{"key":"39483_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/ard.2008.097089","volume":"68","author":"F Cheng","year":"2009","unstructured":"Cheng, F., Guo, Z., Xu, H., Yan, D. & Li, Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 68, 604\u2013606 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"39483_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11033-009-9533-3","volume":"37","author":"XF Zhao","year":"2010","unstructured":"Zhao, X. F. et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol. Biol. Rep. 37, 81\u201385 (2010).","journal-title":"Mol. Biol. Rep."},{"key":"39483_CR28","doi-asserted-by":"publisher","first-page":"e58161","DOI":"10.1371\/journal.pone.0058161","volume":"8","author":"Z Wen","year":"2013","unstructured":"Wen, Z. et al. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One 8, e58161 (2013).","journal-title":"PLoS One"},{"key":"39483_CR29","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Kyttaris, V. C. & Tsokos, G. C. The role of IL-23\/IL-17 axis in lupus nephritis. J. Immunol. 183, 3160-3169 (2009).","DOI":"10.4049\/jimmunol.0900385"},{"key":"39483_CR30","doi-asserted-by":"crossref","unstructured":"Kyttaris, V. C., Zhang, Z., Kuchroo, V. K., Oukka, M. & Tsokos, G. C. Cutting edge: IL- 23 receptor deficiency prevents the development of lupus nephritis in C57BL\/6-lpr\/lpr mice. J Immunol 184, 4605-9 (2010).","DOI":"10.4049\/jimmunol.0903595"},{"key":"39483_CR31","doi-asserted-by":"crossref","unstructured":"Shivakumar, S., Tsokos, G. C. & Datta, S. K. T cell receptor alpha\/beta expressing double-negative (CD4\u2212\/CD8\u2212) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 143, 103-12 (1989).","DOI":"10.4049\/jimmunol.143.1.103"},{"key":"39483_CR32","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/eji.1830270935","volume":"27","author":"AM Oliver","year":"1997","unstructured":"Oliver, A. M., Martin, F., Gartland, G. L., Carter, R. H. & Kearney, J. F. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 27, 2366\u201374 (1997).","journal-title":"Eur J Immunol"},{"key":"39483_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ni1552","volume":"9","author":"HC Hsu","year":"2008","unstructured":"Hsu, H. C. et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9, 166\u201375 (2008).","journal-title":"Nat Immunol"},{"key":"39483_CR34","doi-asserted-by":"crossref","unstructured":"Ding, Y. et al. IL-17RA Is Essential for Optimal Localization of Follicular Th Cells in the Germinal Center Light Zone To Promote Autoantibody-Producing B Cells. J Immunol (2013).","DOI":"10.4049\/jimmunol.1300479"},{"key":"39483_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/art.38229","volume":"66","author":"OB Corneth","year":"2014","unstructured":"Corneth, O. B. et al. Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol. 66, 340\u2013349 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"39483_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2015.10.009","volume":"162","author":"K Ramani","year":"2016","unstructured":"Ramani, K. & Biswas, P. S. Interleukin 17 signaling drives Type I Interferon induced proliferative crescentic glomerulonephritis in lupus-prone mice. Clin. Immunol. 162, 31\u201336 (2016).","journal-title":"Clin. Immunol."},{"key":"39483_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.38955","volume":"67","author":"T Schmidt","year":"2015","unstructured":"Schmidt, T. et al. Function of the Th17\/interleukin-17A immune response in murine lupus nephritis. Arthritis Rheumatol. 67, 475\u2013487 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"39483_CR38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/ard.2007.074484","volume":"67","author":"W Jiang","year":"2008","unstructured":"Jiang, W. & Pisetsky, D. S. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 67, 727\u20138 (2008).","journal-title":"Ann Rheum Dis"},{"key":"39483_CR39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1172\/JCI76344","volume":"125","author":"X Zhu","year":"2015","unstructured":"Zhu, X. et al. Cytosolic HMGB1 controls the cellular autophagy\/apoptosis checkpoint during inflammation. J. Clin. Invest. 125, 1098\u20131110 (2015).","journal-title":"J. Clin. Invest."},{"key":"39483_CR40","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.4049\/jimmunol.181.6.4240","volume":"181","author":"G Liu","year":"2008","unstructured":"Liu, G. et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 181, 4240\u20134246 (2008).","journal-title":"J. Immunol."},{"key":"39483_CR41","doi-asserted-by":"publisher","first-page":"C1267","DOI":"10.1152\/ajpcell.00152.2010","volume":"299","author":"A Friggeri","year":"2010","unstructured":"Friggeri, A. et al. HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am. J. Physiol. Cell. Physiol. 299, C1267\u201376 (2010).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"39483_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12104","volume":"274","author":"SI Valdes-Ferrer","year":"2013","unstructured":"Valdes-Ferrer, S. I. et al. HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C(high) inflammatory monocytes in murine sepsis survivors. J. Intern. Med. 274, 381\u2013390 (2013).","journal-title":"J. Intern. Med."},{"key":"39483_CR43","doi-asserted-by":"publisher","first-page":"861028","DOI":"10.1155\/2013\/861028","volume":"2013","author":"VC Kyttaris","year":"2013","unstructured":"Kyttaris, V. C., Kampagianni, O. & Tsokos, G. C. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed. Res. Int. 2013, 861028 (2013).","journal-title":"Biomed. Res. Int."},{"key":"39483_CR44","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.immuni.2012.08.014","volume":"37","author":"P Pisitkun","year":"2012","unstructured":"Pisitkun, P. et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37, 1104\u20131115 (2012).","journal-title":"Immunity"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39483-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39483-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39483-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:22:34Z","timestamp":1694690554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39483-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["39483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-39483-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"12 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4032"}}